0001209191-22-061947.txt : 20221219
0001209191-22-061947.hdr.sgml : 20221219
20221219164227
ACCESSION NUMBER: 0001209191-22-061947
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221215
FILED AS OF DATE: 20221219
DATE AS OF CHANGE: 20221219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Janku Filip
CENTRAL INDEX KEY: 0001862930
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40522
FILM NUMBER: 221471643
MAIL ADDRESS:
STREET 1: MONTE ROSA THERAPEUTICS, INC.
STREET 2: 40 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02134
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc.
CENTRAL INDEX KEY: 0001826457
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-949-2643
MAIL ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-15
0
0001826457
Monte Rosa Therapeutics, Inc.
GLUE
0001862930
Janku Filip
MONTE ROSA THERAPEUTICS, INC.
645 SUMMER STREET, SUITE 102
BOSTON
MA
02210
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
7.56
2022-12-15
4
A
0
36000
0.00
A
2032-10-02
Common Stock
36000
36000
D
On October 3, 2022, the Reporting Person was granted an option to purchase 36,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On December 15, 2022, the performance criteria underlying such shares were met.
The shares underlying this option shall vest in full on June 15, 2024, subject to the Reporting Person's continued service on such date.
/s/ Ajim Tamboli, Attorney-in-Fact
2022-12-19